Denali Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Denali Therapeutics generated cash of -$357,991,000, which is less than the previous year. Cash used in financing activities reached the amount of $17,820,000 last year. Net change in cash is therefore -$90,863,000.
Cash Flow
| 2015 | -15.05M | -3.06M | 48.85M |
|---|---|---|---|
| 2016 | -72.35M | -219.00M | 300.47M |
| 2017 | -76.63M | -41.16M | 296.32M |
| 2018 | 50.11M | -287.42M | 97.01M |
| 2019 | -151.57M | 147.71M | 6.19M |
| 2020 | 416.15M | -623.20M | 634.74M |
| 2021 | -211.38M | -21.62M | 19.34M |
| 2022 | -244.71M | -141.38M | 310.67M |
| 2023 | -357.99M | 249.30M | 17.82M |
DNLI Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 219.54M | 294.97M | 508.64M | 80.94M | 78.62M | 218.91M | 39.85M | 30.74M | 0 |
Operating activities | |||||||||
Net income | -145.22M | -325.99M | -290.58M | 71.13M | -197.61M | -36.24M | -88.18M | -86.65M | -16.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 16.72M | 10.38M | 8.59M | 8.53M | 7.99M | 7.41M | 3.08M | 1.46M | 121K |
Stock-based compensation expense | 108.10M | 99.84M | 85.24M | 50.35M | 38.37M | 0 | 4.40M | 2.95M | 479K |
| Deferred income tax benefit | 108.10M | 99.84M | 85.24M | 50.35M | 38.37M | 0 | 4.40M | 2.95M | 479K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.43M | 2.27M | 3.70M | -1.62M | 1.03M | -526K | 207K | 161K | 1.67M |
Cash generated by operating activities | -357.99M | -244.71M | -211.38M | 416.15M | -151.57M | 50.11M | -76.63M | -72.35M | -15.05M |
Investing activities | |||||||||
Purchases Of Investments | -1.81B | -1.11B | -1.42B | -1.28B | -369.69M | -557.93M | -179.78M | -226.87M | 0 |
Investments In Property Plant And Equipment | -12.93M | -17.83M | -8.5M | -3.09M | -17.91M | -3.39M | -2.87M | -6.13M | -3.06M |
Acquisitions Net | 0 | 123.55M | 13.12M | 620.11M | -165.63M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 249.30M | -141.38M | -21.62M | -623.20M | 147.71M | -287.42M | -41.16M | -219.00M | -3.06M |
Financing activities | |||||||||
Common Stock Issued | 0 | 296.21M | 19.34M | 614.09M | 6.19M | 0 | 265.61M | 0 | 110K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -3.73M | -297.41M | 0 | 0 | 0 | 0 | 5M |
Cash used in financing activities | 17.82M | 310.67M | 19.34M | 634.74M | 6.19M | 97.01M | 296.32M | 300.47M | 48.85M |
Net Change In Cash | -90.86M | -75.43M | -213.66M | 427.69M | 2.32M | -140.28M | 178.52M | 9.11M | 30.74M |
Cash at end of period | 128.68M | 219.54M | 294.97M | 508.64M | 80.94M | 78.62M | 218.37M | 39.85M | 30.74M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |